BidaskClub Lowers New England Nuclear (LNTH) to Hold

BidaskClub cut shares of New England Nuclear (NASDAQ:LNTH) from a buy rating to a hold rating in a report issued on Tuesday, May 8th.

Several other brokerages also recently commented on LNTH. Zacks Investment Research upgraded shares of New England Nuclear from a sell rating to a hold rating in a research report on Wednesday, May 2nd. TheStreet upgraded shares of New England Nuclear from a d rating to a c- rating in a research report on Monday, March 19th. Finally, ValuEngine downgraded shares of New England Nuclear from a buy rating to a hold rating in a research report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. New England Nuclear currently has a consensus rating of Hold and an average price target of $24.75.

Shares of New England Nuclear traded down $0.10, reaching $14.05, during midday trading on Tuesday, according to Marketbeat. The company’s stock had a trading volume of 2,235 shares, compared to its average volume of 387,925. The company has a current ratio of 3.51, a quick ratio of 2.80 and a debt-to-equity ratio of 7.87. New England Nuclear has a fifty-two week low of $14.20 and a fifty-two week high of $14.45. The company has a market cap of $555.07 million, a price-to-earnings ratio of 14.50, a PEG ratio of 1.41 and a beta of 1.51.



New England Nuclear (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.22 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.22. New England Nuclear had a net margin of 38.32% and a negative return on equity of 145.14%. The company had revenue of $82.63 million during the quarter, compared to the consensus estimate of $81.15 million. During the same period in the previous year, the business earned $0.11 earnings per share. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. equities research analysts forecast that New England Nuclear will post 0.86 earnings per share for the current year.

In other news, insider Michael P. Duffy sold 27,313 shares of the company’s stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $15.30, for a total transaction of $417,888.90. Following the completion of the transaction, the insider now directly owns 191,472 shares in the company, valued at $2,929,521.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael P. Duffy sold 11,492 shares of the company’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $16.60, for a total transaction of $190,767.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,496 shares of company stock valued at $914,934. Company insiders own 1.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of New England Nuclear by 1.7% in the fourth quarter. BlackRock Inc. now owns 3,808,620 shares of the medical equipment provider’s stock worth $77,887,000 after purchasing an additional 63,687 shares during the last quarter. LSV Asset Management boosted its position in New England Nuclear by 57.5% during the fourth quarter. LSV Asset Management now owns 953,906 shares of the medical equipment provider’s stock valued at $19,507,000 after acquiring an additional 348,298 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in New England Nuclear by 73.7% during the third quarter. Dimensional Fund Advisors LP now owns 911,311 shares of the medical equipment provider’s stock valued at $16,221,000 after acquiring an additional 386,771 shares during the last quarter. Renaissance Technologies LLC boosted its position in New England Nuclear by 44.1% during the fourth quarter. Renaissance Technologies LLC now owns 903,400 shares of the medical equipment provider’s stock valued at $18,475,000 after acquiring an additional 276,300 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in New England Nuclear by 24.8% during the fourth quarter. Teachers Advisors LLC now owns 646,336 shares of the medical equipment provider’s stock valued at $13,218,000 after acquiring an additional 128,533 shares during the last quarter. 89.96% of the stock is currently owned by institutional investors.

About New England Nuclear

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply